We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

32 hedge funds and large institutions have $3.18M invested in Theriva Biologics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

0.01% less ownership

Funds ownership: 0.04% → 0.03% (-0.01%)

2% less capital invested

Capital invested by funds: $3.24M → $3.18M (-$56K)

3% less funds holding

Funds holding: 33 → 32 (-1)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

Holders
32
Holders Change
-1
Holders Change %
-3.03%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
8
Reduced
7
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$76.8K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$41.4K
3
Millennium Management
Millennium Management
New York
+$36.6K
4
HF
HRT Financial
New York
+$27.8K
5
Northern Trust
Northern Trust
Illinois
+$24.8K

Top Sellers

Rank Fund Capital Flow
1
Truist Financial
Truist Financial
North Carolina
-$299K
2
Citadel Advisors
Citadel Advisors
Florida
-$76K
3
MP
MSD Partners
New York
-$63.4K
4
BCM
Bridgeway Capital Management
Texas
-$20K
5
TRCT
Tower Research Capital (TRC)
New York
-$13.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.51M +$13.1K +192 +0.9%
BlackRock
2
BlackRock
New York
$538K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$321K +$41.4K +607 +16%
State Street
4
State Street
Massachusetts
$139K +$4.09K +60 +3%
Northern Trust
5
Northern Trust
Illinois
$96K +$24.8K +364 +37%
VF
6
Virtu Financial
New York
$87K -$6.81K -100 -8%
Jane Street
7
Jane Street
New York
$80K +$76.8K +1,127 New
William Blair & Company
8
William Blair & Company
Illinois
$73K +$11.3K +166 +19%
Two Sigma Investments
9
Two Sigma Investments
New York
$47K +$21.6K +317 +94%
Two Sigma Advisers
10
Two Sigma Advisers
New York
$40K -$6.61K -97 -15%
Millennium Management
11
Millennium Management
New York
$38K +$36.6K +537 New
Fisher Asset Management
12
Fisher Asset Management
Washington
$36K – – –
MP
13
MSD Partners
New York
$33K -$63.4K -931 -67%
Renaissance Technologies
14
Renaissance Technologies
New York
$31K +$23.7K +348 +424%
HF
15
HRT Financial
New York
$29K +$27.8K +408 New
UBS Group
16
UBS Group
Switzerland
$23K -$4.84K -71 -18%
IA
17
IFP Advisors
Florida
$13K -$2.73K -40 -73%
TSS
18
Two Sigma Securities
New York
$11K +$10.3K +151 New
LFA
19
Landmark Financial Advisors
Kentucky
$6K – – –
JCM
20
Jacobi Capital Management
Pennsylvania
$5K – – –
Victory Capital Management
21
Victory Capital Management
Texas
$5K +$886 +13 +17%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$5K +$5.11K +75 New
1IA
23
1620 Investment Advisors
Massachusetts
$4K +$4.09K +60 New
TRCT
24
Tower Research Capital (TRC)
New York
$3K -$13.5K -198 -84%
Creative Planning
25
Creative Planning
Kansas
$3K – – –
1
2

TOVX Hedge Fund Activity: Q1 2022 in Review

32 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2022, worth a combined $3.18M — down 1.7% from $3.24M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of TOVX and 8 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 8 added.

The largest buyer was Jane Street, opening a new position worth an estimated $76.8K. The largest seller was Truist Financial, exiting entirely with an estimated $299K sold.

  • 32 institutional investors held Theriva Biologics (TOVX) as of Q1 2022, down from 33 in Q4 2021.
  • Funds reported $3.18M of Theriva Biologics stock for Q1 2022, down 1.7% quarter-over-quarter.
  • 8 funds opened new Theriva Biologics positions in Q1 2022 and 9 closed out, a net change of -1 holder.
  • The largest Theriva Biologics buyer in Q1 2022 was Jane Street, an estimated $76.8K added.
  • The largest Theriva Biologics seller in Q1 2022 was Truist Financial, an estimated $299K sold.

Based on aggregated 13F filings for Q1 2022.